Drug Trial Radar · NCT07709585
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
124
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Jul 31, 2030
Study completion Jul 31, 2030
Sponsor
- Lead sponsor
- Guangzhou University of Traditional Chinese MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Guangdong Provincial Hospital of Traditional Chinese Medicine; Beijing Chest Hospital; Guang'anmen Hospital of China Academy of Chinese Medical Sciences; Sichuan Cancer Hospital and Research Institute; Yueyang Hospital of Integrated Traditional Chinese and Western Medicine; First Affiliated Hospital of Xinjiang Medical University
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, phase II exploratory clinical trial in untreated patients with EGFR-mutant non-small cell lung cancer (stages IIIB-IV) .All participants will receive oral befotertinib monotherapy for 3 weeks first, then serial minimal residual disease (MRD/MRD) testing is performed to adjust subsequent treatment. Patients with positive MRD will receive 4 cycles of pemetrexed plus platinum chemotherapy; patients with negative MRD will continue single-agent befotertinib. After induction, maintenance therapy will be given according to follow-up MRD results. The primary goal is to evaluate progression-free survival guided by dynamic MRD monitoring, and secondary endpoints include objective response rate, disease control rate, safety and MRD clearance rate.
Conditions
- Advanced Non-small Cell Lung Cancer (NSCLC)
- EGFR Exon 19 Deletion Mutation
- EGFR Exon 21 Mutation
- EGFR Exon 21 L858R Mutation
Interventions
BefotinibDrug
Oral administration, initial dose 75 mg once daily; dose adjusted to 100 mg once daily based on safety and clinical benefit. Used as induction, single-agent maintenance, or combined with chemotherapy.
Pemetrexed + Cisplatin /CarboplatinDrug
This is induction combination chemotherapy for MRD-positive patients after initial befotinib monotherapy. Pemetrexed at 500 mg/m² is given intravenously on Day 1 of each 21-day cycle, combined with either Cisplatin (75 mg/m² IV Day 1) or Carboplatin (AUC 5 IV Day 1) at investigator's discretion based on patient renal function and tolerability, for up to 4 cycles. Standard premedication with folic acid, vitamin B12 and dexamethasone is administered per pemetrexed prescribing guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to 48 months after the last participant enrollment,including at least 24 months of follow-up after the last participant is enrolled.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, Guangdong, China · Not yet recruiting
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.